<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024436</url>
  </required_header>
  <id_info>
    <org_study_id>FOENIX-MBC2 TAS-120-201</org_study_id>
    <secondary_id>2019-001164-30</secondary_id>
    <nct_id>NCT04024436</nct_id>
  </id_info>
  <brief_title>A Study of TAS-120 in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor&#xD;
      Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with&#xD;
      the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic&#xD;
      breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who&#xD;
      have previously received conventional therapies to treat their breast cancer, or who are not&#xD;
      able to tolerate certain cancer therapies. This study will also evaluate the safety of taking&#xD;
      futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, non-randomized, multicenter study designed to evaluate the&#xD;
      efficacy and safety of futibatinib (TAS-120) and futibatinib + fulvestrant in up to 168 adult&#xD;
      patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications.&#xD;
      Patients will be enrolled to 1 of 4 treatment cohorts based on diagnosis and FGFR gene&#xD;
      amplification status, and will receive either single agent futibatinib in Cohorts 1-3 or&#xD;
      futibatinib plus fulvestrant in Cohort 4, as follows:&#xD;
&#xD;
        -  Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification&#xD;
&#xD;
        -  Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification&#xD;
&#xD;
        -  Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification&#xD;
&#xD;
        -  Cohort 4 - HR+ HER2- Measurable Disease w/ FGFR1 Amplification&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) - Cohorts 1, 2</measure>
    <time_frame>12 months (estimated)</time_frame>
    <description>Response assessments will be made based on RECIST guidelines (version 1.1, 2009) for solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Benefit Rate (CBR) - Cohort 3</measure>
    <time_frame>12 months (estimated)</time_frame>
    <description>CBR is defined as the proportion of patients with a confirmed response of CR or SD lasting at least 24 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month Progression-free Survival (PFS) rate - Cohort 4</measure>
    <time_frame>12 months (estimated)</time_frame>
    <description>The 6-month PFS rate is defined as the proportion of patients who are alive and progression-free 6 months after the first dose of study therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) - Cohort 3</measure>
    <time_frame>12 months (estimated)</time_frame>
    <description>CR is defined as the disappearance of all target and/or non-target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) - Cohort 4</measure>
    <time_frame>12 months (estimated)</time_frame>
    <description>Response assessments will be made based on RECIST guidelines (version 1.1, 2009) for solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) - Cohort 1,2, and 4</measure>
    <time_frame>12 months</time_frame>
    <description>CBR is defined as the proportion of patient with a confirmed response of CR, PR or SD lasting at least 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month Progression-free Survival (PFS) rate - Cohorts 1-3</measure>
    <time_frame>12 months</time_frame>
    <description>6-month PFS rate is defined as the proportion of patients who are alive and progression-free 6 months after the first dose of study therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>PFS is defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>DOR is defined as the time from first documentation of objective response to the date of death (any cause) or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>OS is defined as the time (in months) from the first dose of study therapy to the date of death (any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) Related to TAS-120 as a monotherapy and in combination with Fulvestrant</measure>
    <time_frame>12 months</time_frame>
    <description>Standard safety monitoring and grading of treatment-emergent adverse events (AEs) will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) Related to Futibatinib as a monotherapy and in combination with Fulvestrant</measure>
    <time_frame>12 months</time_frame>
    <description>Standard safety monitoring and grading of treatment-emergent adverse events (AEs) will be performed using Common Terminology Criteria for Adverse Events (CTCAE - Version 5).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>FGFR 1 High Amplification</condition>
  <condition>FGFR2 Amplification</condition>
  <arm_group>
    <arm_group_label>Futibatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group/Cohort 1 Description HR+ HER2- Measurable Disease w/ FGFR2 Amplification&#xD;
Group/Cohort 2 Description TNBC Measurable Disease w/ FGFR2 Amplification&#xD;
Group/Cohort 3 Description HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Futibatinib plus Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group/Cohort 4 Description HR+ HER2- Measurable Disease w/ FGFR1 Amplification</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Futibatinib</intervention_name>
    <description>Futibatinib 20mg once daily on a 28 day cycle</description>
    <arm_group_label>Futibatinib</arm_group_label>
    <arm_group_label>Futibatinib plus Fulvestrant</arm_group_label>
    <other_name>TAS-120</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Futibatinib plus Fulvestrant</intervention_name>
    <description>Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.</description>
    <arm_group_label>Futibatinib plus Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent&#xD;
&#xD;
          2. Age â‰¥ 18 years of age&#xD;
&#xD;
          3. Histologically or cytologically confirmed recurrent locally advanced or metastatic&#xD;
             breast cancer not amenable to treatment with curative intent, and the following cohort&#xD;
             specific criteria:&#xD;
&#xD;
             A. Cohort 1&#xD;
&#xD;
               -  HR+ HER2- breast cancer harboring an FGFR2 gene amplification.&#xD;
&#xD;
               -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
                  Version 1.1&#xD;
&#xD;
               -  Has received 1-3 prior endocrine-containing therapies and up to 2 prior&#xD;
                  chemotherapy regimens for advanced/metastatic disease&#xD;
&#xD;
               -  Has received prior treatment with a CDK4/6 inhibitor or is ineligible for such&#xD;
                  treatment&#xD;
&#xD;
             B. Cohort 2&#xD;
&#xD;
               -  TNBC harboring an FGFR2 gene amplification&#xD;
&#xD;
               -  Measurable disease per RECIST 1.1&#xD;
&#xD;
               -  Has received at least 1 prior chemotherapy or chemotherapy/immunotherapy&#xD;
                  (PD-L1/PD-1 inhibitors) regimen for advanced/metastatic disease C. Cohort 3&#xD;
&#xD;
               -  TNBC or HR+ HER2- breast cancer harboring an FGFR2 gene amplification&#xD;
&#xD;
               -  Non measurable, evaluable disease per RECIST 1.1. Patients with bone-only disease&#xD;
                  must have lytic or mixed lytic-blastic lesions&#xD;
&#xD;
               -  Other criteria for either HR+ HER2- breast cancer or TNBC should be met as&#xD;
                  described for Cohort 1 and 2, respectively&#xD;
&#xD;
             D. Cohort 4&#xD;
&#xD;
               -  HR+ HER2- breast cancer harboring an FGFR1 high-level gene amplification&#xD;
&#xD;
               -  Measurable disease per RECIST 1.1&#xD;
&#xD;
               -  Has received 1-2 prior endocrine-containing therapies and no more than 1 prior&#xD;
                  chemotherapy regimen for advanced/metastatic disease. Prior treatment with&#xD;
                  fulvestrant is not permitted.&#xD;
&#xD;
               -  Has received prior treatment with a CDK4/6 inhibitor or is ineligible for such&#xD;
                  treatment&#xD;
&#xD;
               -  Pre/peri-menopausal patients must be on goserelin&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          5. Archival or (preferably) fresh tumor tissue must be available&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History and/or current evidence of any of the following disorders:&#xD;
&#xD;
               1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is&#xD;
                  considered clinically significant&#xD;
&#xD;
               2. Ectopic mineralization/calcification, including but not limited to soft tissue,&#xD;
                  kidneys, intestine, or myocardia and lung, considered clinically significant&#xD;
&#xD;
               3. Retinal or corneal disorder confirmed by retinal/corneal examination and&#xD;
                  considered clinically significant&#xD;
&#xD;
          2. Prior treatment with an FGFR inhibitor&#xD;
&#xD;
          3. A serious illness or medical condition(s)&#xD;
&#xD;
          4. Brain metastases that are untreated or clinically or radiologically unstable&#xD;
&#xD;
          5. Pregnant or lactating female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maceij Gil, MD</last_name>
    <phone>609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic - AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Heeney</last_name>
      <phone>855-776-0015</phone>
      <email>cancerclinicaltrialsreferrals@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vance Wright-Browne</last_name>
      <email>clinicaltrials@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - FL</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Arnold</last_name>
      <phone>904-953-3652</phone>
      <email>Arnold.amanda1@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Wright</last_name>
      <phone>727-216-1143</phone>
      <email>clinicaltrials@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viralkumar Bhanderi</last_name>
      <phone>850-877-8166</phone>
      <email>Vbhanderi@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenifer Bar-Nur</last_name>
      <phone>561-472-1696</phone>
      <email>Jbar-nur@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aditya Bardia</last_name>
      <phone>617-724-4800</phone>
      <email>Abardia1@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DF Trial Hotline</last_name>
      <phone>877-338-7425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - MN</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Ihrke</last_name>
      <phone>507-538-5843</phone>
    </contact>
    <contact_backup>
      <last_name>aige Schreifels</last_name>
      <phone>507-266-0539</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SUSAN Stieben</last_name>
      <phone>816-276-4626</phone>
      <email>Susan.Johnson4@hcamidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>844-482-4812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>asksarah@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nisha Unni, MD</last_name>
      <phone>214-648-4180</phone>
      <email>Nisha.Unni@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Hullings</last_name>
      <phone>214-648-7097</phone>
      <email>Melanie.Hullings@UTSouthwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Senthil Damodaran, MD</last_name>
      <phone>713-792-2817</phone>
      <email>sdamodaran@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Cedex</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Fabrice</last_name>
      <phone>+ 33 142 11 50 05</phone>
      <email>Fabrice.andre@gustaveroussy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Bachelot</last_name>
      <phone>+33 478 78 26 54</phone>
      <email>thomas.bachelot@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia - IEO</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Campenni</last_name>
      <phone>39 0257489970</phone>
      <email>GiuseppeMaria.Campenni@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Agnelli</name>
      <address>
        <city>Pinerolo</city>
        <zip>10064</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Tampellini</last_name>
      <phone>39 0121233095</phone>
      <email>mtampellini@aslto3.piemonte.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Cognetti</last_name>
      <phone>39 0652666919</phone>
      <email>segreteriacognetti@ifo.gov.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Champalimaud Clinical Center</name>
      <address>
        <city>Lisboa</city>
        <zip>1400-038</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Benhadji, MD</last_name>
      <phone>609-250-7336</phone>
      <email>clinicaltrialinfo@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Madrid - FJD</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Benhadji, MD</last_name>
      <phone>609-250-7336</phone>
      <email>clinicaltrialinfo@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Madrid - CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Vega</last_name>
      <phone>+34 917 56 78 00</phone>
      <email>oncocare.ciocc@mail.hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCA Healthcare UK</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Crook</last_name>
      <phone>+0203 219 5200</phone>
      <email>Tim.Crook@hcaconsultant.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciara O'Brien</last_name>
      <email>chn-tr.christiebreastresearchteam@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Turner</last_name>
      <phone>+44 207 352 8133</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Futibatinib</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>FGFR</keyword>
  <keyword>TAS-120</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Futibatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

